Clinical Trial Update: Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dexmethylphenidate hydrochloride extended-release capsules in children with ADHD to assess efficacy, tolerability and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dexmethylphenidate HCl Extended-Release Capsules (dexmethylphenidate hydrochloride extended-release)

Snippet

Sponsor: Novartis | Conditions: ADHD, ADD | Phase 3 | Status: COMPLETED